NCT05442190

Topical SGX302 for Mild-to-Moderate Psoriasis

Phase 2 Study Evaluating SGX302 (Synthetic Hypericin) in the Treatment of Mild-to-Moderate Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Soligenix · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.

Conditions

• Psoriasis
• Plaque Psoriasis
• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	Hypericin	SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
DRUG	Placebo	Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.

Timeline

• Start date: 2022-12-14
• Primary completion: 2025-10-22
• Completion: 2025-11-17
• First posted: 2022-07-01
• Last updated: 2026-01-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study